Can pharmacists be liable for dispensing FDA-withdrawn drugs? Downing v. Hyland Pharmacy Explained

The Utah Supreme Court’s decision in Downing v. Hyland Pharmacy clarifies important boundaries around pharmaceutical liability, holding that the learned intermediary rule does not shield pharmacists from negligence claims when they dispense drugs withdrawn from the market by the FDA or manufacturer.

Background and Facts

Steven Downing received fen-phen prescriptions from Hyland Pharmacy from February 1996 until September 2000. After the FDA and manufacturer Wyeth withdrew fenfluramine (Pondimin) from the market, Downing sued the pharmacy for negligently continuing to fill his prescriptions and failing to remove the drug from inventory. The trial court granted summary judgment for the pharmacy, relying on Schaerrer v. Stewart’s Plaza Pharmacy to conclude that pharmacists are protected when filling prescriptions as directed by physicians or manufacturers.

Key Legal Issues

The case presented two related questions: whether a pharmacy may be held liable in negligence for continuing to fill prescriptions for FDA-withdrawn drugs, and whether pharmacies have a duty to warn patients about a drug’s withdrawn status. The central issue was determining the scope of the learned intermediary rule in negligence contexts involving withdrawn medications.

Court’s Analysis and Holding

The Utah Supreme Court distinguished Schaerrer, which involved general side effects of FDA-approved drugs, from the present case involving drugs withdrawn from the market. The court noted that many jurisdictions recognize exceptions to the learned intermediary rule’s protections in negligence cases, particularly for specific problems known to pharmacists such as contraindicated prescriptions or dangerous dosages. The court held that pharmacists owe consumers a duty of reasonable care regarding drugs not authorized for sale by the FDA or manufacturer, while noting that the specific standard of care remains a factual question for remand.

Practice Implications

This decision establishes that pharmaceutical negligence claims may survive summary judgment even under the learned intermediary rule when involving withdrawn drugs. Practitioners should distinguish between general warning duties covered by Schaerrer and specific circumstances involving unauthorized drug sales. The court’s emphasis on developing the factual record regarding withdrawal and professional standards suggests that expert testimony will be crucial in establishing breach of the applicable standard of care.